期刊
INFLAMMATORY BOWEL DISEASES
卷 24, 期 10, 页码 2165-2172出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/ibd/izy134
关键词
biologic; Crohn's disease; drug concentrations; immuonogenicity; inflammatory bowel disease; therapeutic drug monitoring; ulcerative colitis; ustekinumab; vedolizumab
资金
- Abbvie
- Janssen
- Prometheus
- Theradiag
- Buhlmann
In patients with Crohn's disease (CD) and ulcerative colitis (UC), the use of therapeutic drug monitoring (TDM) with TNF-alpha antagonists has led to a personalized approach to optimize treatment and has been shown to be cost-effective. The utility of this TDM-based personalized approach for novel biologic agents, which target different inflammatory pathways, is unclear. Commercial assays for ustekinumab (UST) and vedolizumab (VDZ) are available, but there is little available guidance for clinicians regarding the use of TDM with these drugs. Although there is limited evidence for definitive threshold concentrations for UST and VDZ, this review highlights the available literature on the pharmacokinetics of these medications, the association of clinical and endoscopic outcomes with drug concentrations, and the clinical utility of TDM to guide treatment decisions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据